{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:38:01Z","timestamp":1774546681065,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["U01 CA199240"],"award-info":[{"award-number":["U01 CA199240"]}]},{"name":"Epidemiology Research Core and the National Cancer Institute Center Grant","award":["P30CA022453"],"award-info":[{"award-number":["P30CA022453"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10552-023-01676-0","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:46:19Z","timestamp":1679881579000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort"],"prefix":"10.1007","volume":"34","author":[{"given":"Kalyan","family":"Sreeram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randell","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandana","family":"Kamgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Assad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Ruterbusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3237-6761","authenticated-orcid":false,"given":"Michael S.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,19]]},"reference":[{"key":"1676_CR1","volume-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society (2019) Cancer Facts & Figures 2019. American Cancer Society, Atlanta"},{"issue":"1","key":"1676_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","volume":"12","author":"MJ Hayat","year":"2007","unstructured":"Hayat MJ et al (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20\u201337","journal-title":"Oncologist"},{"issue":"2","key":"1676_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/0284186X.2016.1266089","volume":"56","author":"V Arndt","year":"2017","unstructured":"Arndt V et al (2017) Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncol 56(2):190\u2013197","journal-title":"Acta Oncol"},{"issue":"8","key":"1676_CR4","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","volume":"22","author":"F Mols","year":"2014","unstructured":"Mols F et al (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261\u20132269","journal-title":"Support Care Cancer"},{"issue":"6","key":"1676_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019029","volume":"99","author":"HT Hsu","year":"2020","unstructured":"Hsu HT et al (2020) Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: a cross-sectional study. Medicine (Baltimore) 99(6):e19029","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"1676_CR6","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1007\/s00520-016-3329-5","volume":"24","author":"NR Zanville","year":"2016","unstructured":"Zanville NR et al (2016) Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer 24(11):4779\u20134789","journal-title":"Support Care Cancer"},{"issue":"4","key":"1676_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ et al (2020) Breast Cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(4):452\u2013478","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1676_CR8","first-page":"455","volume":"6","author":"SM Swain","year":"2008","unstructured":"Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455\u2013467","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"1676_CR9","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","volume":"18","author":"EH Bae","year":"2021","unstructured":"Bae EH et al (2021) Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues. Neurotherapeutics 18(4):2384\u20132396","journal-title":"Neurotherapeutics"},{"key":"1676_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuro.2013.05.008","volume":"37","author":"NE LaPointe","year":"2013","unstructured":"LaPointe NE et al (2013) Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 37:231\u2013239","journal-title":"Neurotoxicology"},{"key":"1676_CR11","first-page":"159","volume":"6","author":"WJ Gradishar","year":"2012","unstructured":"Gradishar WJ (2012) Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) 6:159\u2013171","journal-title":"Breast Cancer (Auckl)"},{"issue":"12","key":"1676_CR12","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461\u20132470","journal-title":"Pain"},{"key":"1676_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx162","author":"H Bandos","year":"2018","unstructured":"Bandos H et al (2018) Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx162","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"1676_CR14","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","volume":"34","author":"DL Hershman","year":"2016","unstructured":"Hershman DL et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 34(25):3014\u20133022","journal-title":"J Clin Oncol"},{"key":"1676_CR15","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1002\/cam4.4202","volume":"10","author":"M Kamgar","year":"2021","unstructured":"Kamgar M et al (2021) Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Med 10:6666\u20136676. https:\/\/doi.org\/10.1002\/cam4.4202","journal-title":"Cancer Med"},{"issue":"22","key":"1676_CR16","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1002\/cam4.4328","volume":"10","author":"MR Trendowski","year":"2021","unstructured":"Trendowski MR et al (2021) Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes. Cancer Med 10(22):8151\u20138161","journal-title":"Cancer Med"},{"issue":"9","key":"1676_CR17","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.pec.2019.04.012","volume":"102","author":"R Knoerl","year":"2019","unstructured":"Knoerl R et al (2019) Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches. Patient Educ Couns 102(9):1636\u20131643","journal-title":"Patient Educ Couns"},{"issue":"4","key":"1676_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1055-9965.EPI-18-0123","volume":"28","author":"JL Beebe-Dimmer","year":"2019","unstructured":"Beebe-Dimmer JL et al (2019) The Detroit Research on Cancer Survivors (ROCS) pilot study: a focus on outcomes after cancer in a racially diverse patient population. Cancer Epidemiol Biomarkers Prev 28(4):666\u2013674","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1676_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","volume":"18","author":"HL Cheng","year":"2020","unstructured":"Cheng HL et al (2020) Psychometric testing of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT\/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes 18(1):246\u2013246","journal-title":"Health Qual Life Outcomes"},{"key":"1676_CR20","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.21625.1","author":"R Gordon-Williams","year":"2020","unstructured":"Gordon-Williams R, Farquhar-Smith P (2020) Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.21625.1","journal-title":"F1000Res"},{"key":"1676_CR21","unstructured":"Training.seer.cancer.gov. 2022.\u00a0Summary Staging | SEER Training. [online] Available at: <https:\/\/training.seer.cancer.gov\/staging\/systems\/summary\/>"},{"key":"1676_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/2193-1801-3-366","volume":"3","author":"B Bhatnagar","year":"2014","unstructured":"Bhatnagar B et al (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366","journal-title":"Springerplus"},{"issue":"5","key":"1676_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1188\/17.ONF.580-588","volume":"44","author":"EM Lavoie Smith","year":"2017","unstructured":"Lavoie Smith EM et al (2017) The content validity of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure. Oncol Nurs Forum 44(5):580\u2013588","journal-title":"Oncol Nurs Forum"},{"issue":"2","key":"1676_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11764-017-0662-8","volume":"12","author":"C Miaskowski","year":"2018","unstructured":"Miaskowski C et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors\u2019 symptom burden and quality of life. J Cancer Surviv 12(2):234\u2013245","journal-title":"J Cancer Surviv"},{"issue":"23","key":"1676_CR25","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","volume":"35","author":"KM Winters-Stone","year":"2017","unstructured":"Winters-Stone KM et al (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35(23):2604\u20132612","journal-title":"J Clin Oncol"},{"issue":"2","key":"1676_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","volume":"159","author":"T Bao","year":"2016","unstructured":"Bao T et al (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327\u2013333","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1676_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00520-021-06502-4","volume":"30","author":"C Teng","year":"2021","unstructured":"Teng C et al (2021) Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Support Care Cancer 30(1):33\u201347","journal-title":"Support Care Cancer"},{"issue":"17","key":"1676_CR28","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/cncr.32175","volume":"125","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA et al (2019) Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer 125(17):2945\u20132954","journal-title":"Cancer"},{"key":"1676_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-00988-x","author":"HC Timmins","year":"2021","unstructured":"Timmins HC et al (2021) Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. https:\/\/doi.org\/10.1007\/s11764-021-00988-x","journal-title":"J Cancer Surviv"},{"issue":"9","key":"1676_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ejca.2011.09.029","volume":"48","author":"MA Khattak","year":"2012","unstructured":"Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, Maddern G, Roder D, Price TJ (2012) Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer 48(9):1293\u20131298. https:\/\/doi.org\/10.1016\/j.ejca.2011.09.029","journal-title":"Eur J Cancer"},{"issue":"2","key":"1676_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.critrevonc.2010.06.005","volume":"79","author":"P Barth\u00e9l\u00e9my","year":"2011","unstructured":"Barth\u00e9l\u00e9my P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V, Rob L, Bergerat JP, Kurtz JE (2011) Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 79(2):196\u2013204","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1676_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/tbj.12726","volume":"23","author":"M Meresse","year":"2017","unstructured":"Meresse M, Bouhnik AD, Bendiane MK, Retornaz F, Rousseau F, Rey D, Giorgi R (2017) Chemotherapy in old women with breast cancer: is age still a predictor for under treatment? Breast J 23(3):256\u2013266. https:\/\/doi.org\/10.1111\/tbj.12726","journal-title":"Breast J"},{"issue":"6","key":"1676_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jgo.2019.01.010","volume":"10","author":"M Zahiri","year":"2019","unstructured":"Zahiri M et al (2019) Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults\u2014Toward an early diagnosis of CIPN. J Geriatr Oncol 10(6):960\u2013967","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"1676_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","volume":"20","author":"SL Wolf","year":"2012","unstructured":"Wolf SL et al (2012) The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20(3):625\u2013632","journal-title":"Support Care Cancer"},{"issue":"1","key":"1676_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/jns.12306","volume":"24","author":"G Cavaletti","year":"2019","unstructured":"Cavaletti G et al (2019) Patients\u2019 and physicians\u2019 interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(1):111\u2013119","journal-title":"J Peripher Nerv Syst"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-023-01676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-023-01676-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-023-01676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T17:05:57Z","timestamp":1681578357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-023-01676-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1007\/s10552-023-01676-0","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,19]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark K. Greenwald: Honoraria for Consulting\/Speaker\u2014Indivior Inc. All other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) at Wayne State University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}